Skip to content
Buy This GLP
← Research
Safety

How Much Protein Do You Need on a GLP-1?

A medical advisory discusses 80–120 grams a day as one option during GLP-1 treatment for obesity. Age, body size and kidney health can change the target.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Protein as a share of what you eat, and as an amountbeforetotal energyafterless total energyThe same protein share can mean fewer grams.Illustration only. Bar lengths do not represent trial results.

A 2025 advisory from four medical and nutrition societies discusses 80–120 grams of protein per day as one practical option for adults using GLP-1 therapy for obesity. The advisory also discusses 1.2–1.6 grams per kilogram per day, a range proposed during active weight loss. In people with obesity, using current body weight can overestimate protein needs. The advisory says it remains unclear which weight to use[1].

Why eating less can reduce protein intake

Our guide to nutrition shortfalls explains why it can be harder to get enough nutrients when portions shrink. Protein has the same arithmetic: if the percentage of energy from protein stays constant and total energy falls, protein grams fall too.

In a small crossover study of adults with type 2 diabetes, energy intake at a test lunch was 18% lower with liraglutide than with placebo, with no statistically significant change in the mix of protein, fat and carbohydrate [2]. In another trial, participants with type 2 diabetes ate an average of 6.5 grams less protein at a test meal after 10 weeks of liraglutide than at baseline [3]. These meal tests cannot establish how many grams people eat over a full day.

How protein fits with muscle health

Our guide to lean mass and muscle during GLP-1 treatment explains what body composition scans can measure. Dietary studies rarely measure protein intake, muscle size, strength and physical function together. That makes it hard to tell whether changes in any one of those outcomes are due to lower protein intake [4].

The joint advisory emphasizes both adequate protein and resistance training[1]. Older adults may also have a reduced muscle-building response to protein, one reason to consider age and muscle function when setting a goal[4].

Frequently asked

How much protein do you need on a GLP-1?
A 2025 multisociety advisory discusses 80–120 grams per day as one practical option for adults treated for obesity. The appropriate amount varies with body size, age, activity and health. A clinician or dietitian can help choose a target.
Can GLP-1 therapy reduce how much protein you eat?
Yes. If people eat fewer calories while getting the same share of calories from protein, they consume fewer grams of protein. Small meal studies have observed this with liraglutide, but they do not measure day-to-day intake.
Does eating less protein explain muscle loss?
Studies rarely measure protein intake and muscle mass, strength and function together. Current research cannot establish how much of any observed change in muscle is due to lower protein intake.

Sources

  1. [1] Mozaffarian D, et al. (2025). Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory Obesity. Source
  2. [2] Flint A, Kapitza C, Zdravkovic M (2013). The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment Diabetes, Obesity and Metabolism. Source
  3. [3] Quast DR, et al. (2021). Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes Diabetes, Obesity and Metabolism. Source
  4. [4] Prokopidis K, et al. (2026). Risk of protein intake deficiency during treatment with GLP-1 and GIP/GLP-1 receptor agonists: considerations for secondary sarcopenia Advances in Therapy. PMID 42631799
  5. [5] Kidney Disease: Improving Global Outcomes CKD Work Group (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, section 3.3.1 Kidney International. Source

More in Safety